Article

Seasonal maintenance of influenza vaccine-induced antibody response in kidney transplant recipients.

Division of Nephrology, Vanderbilt University Medical Center, Nashville, Tenn., USA.
American Journal of Nephrology (Impact Factor: 2.65). 08/2012; 36(3):201-7. DOI: 10.1159/000341653
Source: PubMed

ABSTRACT Background/Aims: Although annual influenza vaccination is recommended for kidney transplant recipients, efficacy as reflected by serum antibody titers has not been well studied beyond 1 month in kidney transplant recipients. Methods: We performed a single-center prospective cohort study of 51 kidney transplant recipients and 102 healthy controls receiving the 2006-2007 influenza vaccine. Anti-hemagglutinin antibody titers to A/H1N1, A/H3N2, and B were measured before and 1 month after vaccination, and again at the end of influenza season. The primary outcome was the proportion of participants maintaining seroprotection (antibody titer ≥1:32) for the duration of the influenza season after influenza vaccination. Results: Median follow-up time was 175 and 155 days in the transplant and control groups, respectively. For types A/H1N1 and B, a similar high proportion of the transplant and control groups (88.5 and 81.6% vs. 83.7 and 74.2% for A/H1N1 and B, respectively) maintained seroprotection. For type A/H3N2, significantly less of the transplant group (66.7%) versus the control group (90%) maintained a protective influenza vaccine response (odds ratio 0.21, 95% confidence interval 0.07-0.64). This difference disappeared in adjusted analyses. Actual geometric mean titers decreased significantly within both groups (p < 0.001) but this did not differ between groups. Conclusions: Once they have developed protective vaccine-induced antibody responses to influenza vaccine, kidney transplant recipients are able to maintain adequate protective levels of antibody compared with healthy controls.

0 Bookmarks
 · 
129 Views
  • [Show abstract] [Hide abstract]
    ABSTRACT: Aim: To clarify the immunogenicity and safety of influenza vaccine in patients with end-stage kidney disease (ESKD) on dialysis or who have received a kidney transplant. Methods: Sixty adolescents and young adults with ESKD (25 on hemodialysis and 35 kidney transplant recipients) were randomized 1:1 to receive a traditional trivalent split virion vaccine (TIIV) or a virosome-adjuvanted trivalent inactivated influenza vaccine (VATIIV). The immunogenicity and safety of the two vaccines was evaluated and compared with the findings observed in 30 healthy subjects of similar age and gender distribution who received TIIV. Results: The results indicate that the immune response of the patients to TIIV and VATIIV were similar. The administered vaccines were safe and well tolerated, and no advantage was found with the use of VATIIV. Conclusion: Given the potential clinical relevance of influenza in patients with ESKD, these findings support the official recommendation that they should receive annual influenza vaccinations.
    Expert Review of Vaccines 06/2014; · 4.22 Impact Factor
  • [Show abstract] [Hide abstract]
    ABSTRACT: Patients with heart failure (HF) have lower initial antibody responses to the influenza vaccine compared to healthy individuals. Whether antibody titers wane faster in this population remains unknown. We studied 62 HF patients (18 ischemic, 44 idiopathic) and 40 healthy controls (HC) during the 2006/2007 and 2007/2008 influenza seasons. Antibody titers were measured before, and 2-4 weeks, and 11-12 months after vaccination. Serum antibody production was measured by hemagglutination inhibition assay, and antibody titers to individual vaccine viral strains between HF and HC were compared following the influenza season to measure persistence of antibody response. All participants demonstrated early antibody seroprotection (titers 40 hemmaglutination inhibition units [HAU] to 1 strain). While antibody titers waned over time in both groups, titers to A/H3N2 and A/H1N1 strains decreased more in HF participants compared to HC (p=0.004 and p=0.04, respectively). Titers to the B-type strain decreased to below seroprotective levels in both groups. Antibody titers to influenza A vaccine strains wane to below seroprotective levels in HF patients compared to HC, despite similar rates of initial seroprotection and seroconversion. These findings suggest that HF patients may remain at increased risk for influenza infection despite annual vaccination.
    Journal of cardiac failure 12/2013; · 3.07 Impact Factor
  • Source
    [Show abstract] [Hide abstract]
    ABSTRACT: Immunosuppressive treatments increase the life-long risk of solid organ transplant (SOT) recipients for severe infections, some of which are vaccine-preventable. In this review of the literature published during the last 15 months, we critically summarize vaccine-oriented articles in SOT candidates or recipients. Because of previously reported differences, vaccine-specific studies are needed for each type of SOT recipients. Thanks to new data gathered during the H1N1/2009 influenza pandemic, recent research mainly focused on influenza vaccination, especially in kidney transplantation. Lung transplantation, mycophenolate treatment, increasing age and end-stage organ failure were frequently identified as risk factors for nonresponse to immunization in general. New evidence concerning the safety of immunizing SOT recipients with live-attenuated vaccines is obtained. During this last year, more encouraging data have been published regarding safety and immunogenicity of vaccination in SOT recipients. New inventive strategies should be studied to overcome missed opportunities for vaccinating SOT candidates and recipients, and to promote the most effective vaccination schedule and follow-up.
    Current opinion in organ transplantation 07/2013; · 3.27 Impact Factor

Full-text

Download
12 Downloads
Available from
Sep 11, 2014